Wyeth, LLC Patent applications |
Patent application number | Title | Published |
20160089521 | IMPLANTABLE SHUNT OR CATHETER ENABLING GRADUAL DELIVERY OF THERAPEUTIC AGENTS - An implantable catheter or shunt for draining fluid from a body cavity. The catheter or shunt body has a wall structure that carries one or more therapeutic agents in a manner enabling release of the therapeutic agent from the wall structure in situ after surgical implantation of the catheter or shunt body. The therapeutic agent can be gradually released over time to prevent infection, inhibit tissue ingrowths, and/or provide some other desired medicinal purpose. As an example, the therapeutic agent can be rapamycin or an mTOR inhibitor. According to some contemplated embodiments of the present invention, the therapeutic agent carried by the catheter/shunt is rechargeable or refillable in situ so that the therapeutic agent can be gradually released from the catheter/shunt over the expected useful life of the catheter/shunt. | 03-31-2016 |
20160002331 | ANTI-NOTCH1 ANTIBODIES - The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions. | 01-07-2016 |
20150315138 | PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES - This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates. | 11-05-2015 |
20150272909 | Pharmaceutical Composition Containing Sympathomimetic Amine Salt and Co-distillable Additive - A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base. | 10-01-2015 |
20150231099 | Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen - Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets. | 08-20-2015 |
20150118223 | USE OF TAU TO MONITOR IMMUNOTHERAPY - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau. | 04-30-2015 |
20150099865 | PROCESSES FOR MAKING HYDRAZIDES - A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody. | 04-09-2015 |
20150076012 | CAP WITH ADDITIVE CHAMBER AND ASSOCIATED PACKAGING UNIT - The present invention comprises a cap ( | 03-19-2015 |
20150024484 | Antibody Inhibitors of GDF-8 and Uses Thereof - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 01-22-2015 |
20150018421 | Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 01-15-2015 |
20140363463 | SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES - A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular | 12-11-2014 |
20140342047 | Embedded Liquid Lubricants for Tableting - The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided. | 11-20-2014 |
20140328925 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 11-06-2014 |
20140249190 | Fast Dissolving Tablet - The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided. | 09-04-2014 |
20140249171 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 09-04-2014 |
20140248239 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS - Compounds of formula I | 09-04-2014 |
20140194398 | Tanaproget Compositions Containing Ethinyl Estradiol - Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol. | 07-10-2014 |
20140190129 | Child Resistant Bulk Dose Dispensing Unit - Child-resistant bulk dose dispensing packaging unit, and a method for opening the packaging unit, including a container and a lid engaged with the container. The container includes a reservoir, an aperture at a top end of the reservoir, and a protrusion extending from a surface of the container. The lid engages with the container and slides between a closed position and an open position. The lid includes a top wall, a side wall extending down from an outer edge of the top wall, and a post configured to engage the protrusion at a first position when the lid is closed so as to keep the lid closed. At least a portion of the post extends substantially parallel to the side wall at a distance from the side wall. Pressing the side wall inward places the post at a second position, wherein at the second position the post is disengaged from the protrusion. | 07-10-2014 |
20140142187 | Pharmaceutical Suspension Composition - An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously. | 05-22-2014 |
20140113329 | HIGH-CELL DENSITY FED-BATCH FERMENTATION PROCESS FOR PRODUCING RECOMBINANT PROTEIN - Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and optionally continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions and compositions for use in the methods of the present invention, are provided. | 04-24-2014 |
20140107147 | Antineoplastic Combinations Containing HKI-272 and Vinorelbine - A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described. | 04-17-2014 |
20140094458 | Cyclic Progestin Regimens and Kits - A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen. | 04-03-2014 |
20140086920 | Antagonist Antibodies against GDF-8 and Uses in Treatment of ALS and Other GDF-8 Associated Disorders - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 03-27-2014 |
20140081010 | PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES - This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates. | 03-20-2014 |
20140081005 | ANTIBODY-DRUG CONJUGATES - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same. | 03-20-2014 |
20140050721 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 - A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described. | 02-20-2014 |
20140017312 | Multi-vitamin and Mineral Nutritional Supplements - The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans. | 01-16-2014 |
20140017271 | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from | 01-16-2014 |
20140004203 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | 01-02-2014 |
20140004184 | COATED TABLET FORMULATIONS AND USES THEREOF | 01-02-2014 |
20130337058 | Micronized Tanaproget and Compositions Containing Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 12-19-2013 |
20130330407 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 12-12-2013 |
20130330371 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 12-12-2013 |
20130266594 | ANTI-NOTCH1 ANTIBODIES - The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions. | 10-10-2013 |
20130252998 | CCI-779 FORMULATIONS FOR PARENTERAL ADMINISTRATION - This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent. | 09-26-2013 |
20130251807 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 09-26-2013 |
20130244307 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 09-19-2013 |
20130217597 | Compatible Display Vector Systems - The present invention provides a polynucleotide vector system used during polypeptide display that can be used to facilitate transfer of pools of polynucleotides encoding antigen binding proteins of interest. The present invention also provides methods that allow seamless conversion of pools of polynucleotides encoding antigen binding proteins using a restriction enzyme digestion and ligation strategy. | 08-22-2013 |
20130211053 | PROCESSES FOR MAKING HYDRAZIDES - A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody. | 08-15-2013 |
20130209501 | Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens - The present invention relates to immunogenic compositions, comprising polypeptides isolated from | 08-15-2013 |
20130209453 | USE OF TAU TO MONITOR IMMUNOTHERAPY - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau. | 08-15-2013 |
20130197198 | Removal Of High Molecular Weight Aggregates Using Hydroxyapatite Chromatography - This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation. | 08-01-2013 |
20130196930 | POLYNUCLEOTIDES ENCODING RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided. | 08-01-2013 |
20130171194 | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS - The present invention relates to stable formulations of | 07-04-2013 |
20130156767 | METHOD FOR TREATING CACHEXIA USING ANTAGONIST ANTIBODIES AGAINST GDF-8 - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 06-20-2013 |
20130150554 | CELL CULTURE OF GROWTH FACTOR-FREE ADAPTED CELLS - The present invention provides improved cell culture systems that allow optimum production of recombinant proteins. Among other things, the present invention provides methods of cell culture including a step of cultivating cells adapted to growth factor-free medium in a cell culture system that provides at least one growth factor. | 06-13-2013 |
20130143827 | TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF - A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided. | 06-06-2013 |
20130142838 | COMPOSITIONS CONTAINING MICRONIZED TANAPROGET PREPARED BY WET GRANULATION - Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic to disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 06-06-2013 |
20130116327 | Burst Drug Release Compositions - A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation. | 05-09-2013 |
20130115250 | Burst Drug Release Compositions - Solid dose compositions comprising at least one low solubility pharmaceutically active ingredient, at least one low solubility filler and at least one controlled release agent. comprising at least one poorly soluble pharmaceutically active ingredient, a insoluble binder and at least one controlled release agent along with a method of manufacturing said composition are disclosed. Methods for making these compositions are also disclosed. | 05-09-2013 |
20130084593 | RATIONALLY DESIGNED MEDIA FOR CELL CULTURE - This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and media disclosed herein; and pharmaceuticals compositions containing such polypeptides. The rationally designed media contain a concentration of an amino acid that is calculated for use in cell mass, a concentration of the amino acid that is calculated for use in cell maintenance, and a concentration of the amino acid that is calculated for incorporation into the polypeptide of interest. | 04-04-2013 |
20130084245 | PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY - The present invention provides methods of monitoring Aβ-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the Aβ-directed immunotherapy and if necessary adjustment of the immunotherapy regime. | 04-04-2013 |
20130072881 | VACCINE FORMULATIONS - An immunogenic composition comprising a plurality of capsular polysaccharides from | 03-21-2013 |
20130072480 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators - Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: | 03-21-2013 |
20130065928 | BIOMARKERS FOR PI3K-DRIVEN CANCER - Disclosed is the discovery that the mTORC2 complex plays a role in the regulation of PKN3 phosphorylation at the turn motif threonine; and the use of the phosphorylation status of the turn motif threonine of PKN3 as a biomarker. In some embodiments, the phosphorylation status of the turn motif threonine of PKN3 is determined using an antibody that specifically binds to the turn motif threonine of a PKN3 protein, such as an anti-phosphoT860 antibody. In some embodiments, the invention relates to methods for screening compounds that have cancer therapeutic potential, methods for diagnosing cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial, methods for treating a patient suffering from cancer, and methods for determining the effectiveness of a particular treatment regimen. | 03-14-2013 |
20130040980 | CCI-779 CONCENTRATE FORMULATIONS - This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent. | 02-14-2013 |
20130034580 | NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like. | 02-07-2013 |
20130023032 | Synergistic Attenuation of Vesicular Stomatitis Virus, Vectors Thereof and Immunogenic Compositions Thereof - The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof. | 01-24-2013 |
20130022547 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated | 01-24-2013 |
20130018184 | METHODS OF PREPARING POLYMORPHIC FORM A OF BAZEDOXIFENE ACETATE - The present invention relates to methods of preparing polymorphic Form A of bazedoxifene acetate and polymorphic Form A prepared by such methods. | 01-17-2013 |
20130018179 | PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES - This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates. | 01-17-2013 |
20130012702 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS - Methods for purifying a compound of formula I are provided, wherein A, B, X, Q, and R | 01-10-2013 |
20130011418 | Antibody-Drug Conjugates - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same. | 01-10-2013 |
20130005723 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS - Compounds of formula I | 01-03-2013 |
20120322104 | SYSTEMS AND METHODS FOR PROTEIN PRODUCTION - The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XBP1- or ATF6-mediated UPR pathway. | 12-20-2012 |
20120308560 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 - A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described. | 12-06-2012 |
20120308483 | Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 12-06-2012 |
20120294983 | Nutritional Formulation - The present invention relates to nutritional supplements that provide an adult with essential vitamins and minerals that may be lacking in the adult's diet and prevent chronic diseases, such as osteoporosis. A number of combinations of nutrients in set ratios are provided to increase the body's ability to absorb and use the nutrients. These combinations are important in helping the body reach the proper balance required for maximized function. Because adults over the age of 50 years have different nutritional needs, nutritional supplements specifically designed for them are also provided. | 11-22-2012 |
20120282248 | PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY - The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody. | 11-08-2012 |
20120276137 | COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising | 11-01-2012 |
20120276102 | METHODS OF TREATMENT UTILIZIING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 11-01-2012 |
20120270896 | Antineoplastic Combinations Containing HKI-272 and Vinorelbine - A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described. | 10-25-2012 |
20120269841 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 10-25-2012 |
20120264919 | INTERLEUKIN-21 RECEPTOR BINDING PROTEINS - The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 10-18-2012 |
20120252884 | Modified and Stabilized GDF Propeptides and Uses Thereof - Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis). | 10-04-2012 |
20120252769 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS - The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: | 10-04-2012 |
20120251558 | ANTIBODY-DRUG CONJUGATES - Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same. | 10-04-2012 |
20120244113 | IMMUNOGENIC COMPOSITION AND METHODS - A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The method also includes administering to the subject an effective amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method. | 09-27-2012 |
20120237542 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 09-20-2012 |
20120220558 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives - The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: | 08-30-2012 |
20120208782 | Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of | 08-16-2012 |
20120207706 | A-Beta Immunogenic Peptide Carrier Conjugates and Methods of Producing Same - The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods. | 08-16-2012 |
20120190721 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain. | 07-26-2012 |
20120141522 | RECOMBINANT PROTECTIVE PROTEIN FROM STREPTOCOCCUS PNEUMONIAE - The present invention discloses amino acid sequences and nucleic acid sequences relating to a | 06-07-2012 |
20120141497 | METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS - The present invention provides, among other things, methods of purifying or recovering proteins, in particular, small modular immunopharmaceutical (SMIPs™) proteins, from protein preparations containing high molecular weight (HMW) aggregates and other impurities based on hydroxyapatite chromatography. In some embodiments, the hydroxyapatite chromatography is used in combination with affinity chromatography and/or ion exchange chromatography. In some embodiments, inventive methods according to the invention involve no more than three chromatography steps. The present invention also provides proteins such as SMIPs™ purified according to the invention and pharmaceutical compositions containing the same. | 06-07-2012 |
20120138537 | METHOD OF WEAK PARTITIONING CHROMATOGRAPHY - This invention relates to methods of using weak partitioning chromatography for the purification of a product from a load fluid containing one or more impurities. Further, the invention relates to methods of weak partitioning chromatography defined by operating conditions which cause a medium to bind least 1 mg of product per mL of medium, or alternatively, defined by a partition coefficient of at least 0.1. | 06-07-2012 |
20120134959 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds. | 05-31-2012 |
20120130052 | PROCESSES FOR MAKING HYDRAZIDES - A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody. | 05-24-2012 |
20120129801 | BLOOD PARASITICIDE - This application relates to compositions and methods of treating tick-born parasitic diseases in livestock with the compositions. The compositions include imidocarb dipropionate, cyanocobalamin vitamin B12, and pharmaceutically acceptable carriers. | 05-24-2012 |
20120115858 | Polymorph Form II of Tanaproget - Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject. | 05-10-2012 |
20120114748 | Tanaproget Compositions Containing Ethinyl Estradiol - Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol. | 05-10-2012 |
20120114646 | LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS - The present invention provides, among other things, stable formulations for small modular immunopharmaceutical (SMIP™) proteins. In some embodiments, the present invention provides a formulation containing a lyophilized mixture of a small modular immunopharmaceutical protein, wherein less than 7% of the lyophilized small modular immunopharmaceutical protein exists in aggregated form. Formulations according to the invention may contain buffering agents, stabilizers, bulking agents, surfactants and/or other excipients. The present invention also provides formulations for lyophilization, reconstitution and methods of use thereof. | 05-10-2012 |
20120107928 | Antibody Inhibitors of GDF-8 and Uses Thereof - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 05-03-2012 |
20120107327 | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from | 05-03-2012 |
20120093852 | NON-LIPIDATED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS - The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B | 04-19-2012 |
20120071350 | TUMOR-INITIATING CELLS AND METHODS FOR USING SAME - Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof. | 03-22-2012 |
20120070495 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 03-22-2012 |
20120070379 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 03-22-2012 |
20120064600 | ANTI-5T4 ANTIBODIES AND USES THEREOF - Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same. | 03-15-2012 |
20120059380 | Bone Cement Delivery Systems and Related Kits and Methods - A bone cement delivery method that includes inserting a portion of a bone cement delivery device into a femoral neck of a femur of a patient, and injecting bone cement paste into the femoral neck of the patient via the bone cement delivery system. | 03-08-2012 |
20120059190 | NOVEL NITRATION OF TETRACYCLINES - The invention in one embodiment is directed to a method of preparing a compound of formula 1, | 03-08-2012 |
20120046227 | DESIGNER OSTEOGENIC PROTEINS - The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics. | 02-23-2012 |
20120045476 | LIVE ATTENUATED MYCOPLASMA STRAINS - The present invention provides live, attenuated | 02-23-2012 |
20120041042 | Scent Ectoparasiticidal Formulation - The present invention provides an improved-scent composition comprising metaflumizone, as well as a method for protecting against ectoparasite infestations in a warm-blooded animal. | 02-16-2012 |
20120034630 | Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 02-09-2012 |
20120028878 | Membrane Evaporation for Generating Highly Concentrated Protein Therapeutics - The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result in protein solution concentrations not previously achievable by conventional ultrafiltration methods, e.g., protein solution concentrations of greater than about 260 grams of protein per liter of solution. | 02-02-2012 |
20120022621 | THERMAL DEVICE - A method of delivering safe therapeutic heat to an unconscious or inert subject is described, wherein a disposable device is applied to the user that provides a consistent skin side temperature, wherein said device comprises a thermal source comprising a particulate exothermic composition; and a primary insulative material disposed on a skin side of the thermal source that delivers heat while protecting the subject from burns; wherein said device provides a rate of temperature change of less than about 0.8. | 01-26-2012 |
20120016118 | CYANOPYRROLE CONTAINING CYCLIC CARBAMATE AND THIOCARBAMATE BIARYLS AND METHODS FOR PREPARING THE SAME - Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided: | 01-19-2012 |
20120016106 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 01-19-2012 |
20120014975 | MODIFIED SINGLE DOMAIN ANTIGEN BINDING MOLECULES AND USES THEREOF - The invention relates to modified single domain antigen binding molecules, e.g., SDAB molecules, in particular TNFα-binding SDAB molecules. Method of preparing, and using the modified single domain antigen binding molecules described herein, to treat, e.g., TNFα-associated disorders, are also disclosed. | 01-19-2012 |
20120010240 | CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR - A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value. | 01-12-2012 |
20120010205 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS - Disclosed are quinoline esters of Formula (I): | 01-12-2012 |
20120005768 | Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 01-05-2012 |
20120003265 | IMMUNOGENIC COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV - The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens. | 01-05-2012 |
20120003212 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 01-05-2012 |
20110305726 | Infectious Bronchitis Vaccines Derived From IB-qx-like Vaccine Strains - The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses. | 12-15-2011 |
20110305725 | METHODS AND COMPOSITIONS FOR IMMUNIZING PIGS AGAINST PORCINE CIRCOVIRUS - The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS. | 12-15-2011 |
20110294845 | PARENTERAL FORMULATIONS - This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent. | 12-01-2011 |
20110288135 | Fast Dissolving Tablet - The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided. | 11-24-2011 |
20110287042 | A-Beta Immunogenic Peptide Carrier Conjugates and Methods of Producing Same - The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods. | 11-24-2011 |
20110280955 | Nutritional Supplements For 50+ Individuals For Improving Vitality, Immunity, Eye And Bone Health - A nutritional supplement for adults fifty years and older, and methods of use thereof, are provided that are designed to be most effective in optimizing health, improving vitality and immunity, and improving, aiding, eye and bone health. | 11-17-2011 |
20110262435 | IL-13 BINDING AGENTS - Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed. | 10-27-2011 |
20110250198 | ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis. | 10-13-2011 |
20110243977 | SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES - β-hemolytic streptococci polynucleotides, polypeptides, particularly | 10-06-2011 |
20110229413 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment. | 09-22-2011 |
20110226772 | Child Resistant Bulk Dose Dispensing Unit - Child-resistant bulk dose dispensing packaging unit, and a method for opening the packaging unit, including a container and a lid engaged with the container. The container includes a reservoir, an aperture at a top end of the reservoir, and a protrusion extending from a surface of the container. The lid engages with the container and slides between a closed position and an open position. The lid includes a top wall, a side wall extending down from an outer edge of the top wall, and a post configured to engage the protrusion at a first position when the lid is closed so as to keep the lid closed. At least a portion of the post extends substantially parallel to the side wall at a distance from the side wall. Pressing the side wall inward places the post at a second position, wherein at the second position the post is disengaged from the protrusion. | 09-22-2011 |
20110223250 | MULTI-VITAMIN AND MINERAL NUTRITIONAL SUPPLEMENTS - The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans. | 09-15-2011 |
20110212953 | Polymorph Form II of Tanaproget - Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject. | 09-01-2011 |
20110212099 | METHODS OF MODULATING IL-22 AND IL-17 - The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23 | 09-01-2011 |
20110201791 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 08-18-2011 |
20110189099 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated | 08-04-2011 |
20110178311 | Purification of Progesterone Receptor Modulators - Processes are provided for purifying a compound of the structure (I): | 07-21-2011 |
20110172393 | NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like. | 07-14-2011 |
20110171263 | COMPOSITIONS AND METHODS OF USE OF ORF-1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS - The present invention relates to polynucleotides encoding | 07-14-2011 |
20110165257 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA - The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors. | 07-07-2011 |
20110165241 | BAZEDOXIFENE FORMULATIONS WITH ANTIOXIDANTS - This disclosure relates to pharmaceutical compositions comprising bazedoxifene and an antioxidant such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, or BHA/BHT, substantially free of ascorbic acid, as well as methods of making such compositions. Also provided are methods of enhancing dissolution stability and/or enhancing bioavailability of bazedoxifene in a formulation containing an antioxidant, and methods of reducing interactions of at least one of bazedoxifene and hydroxymethyl cellulose with at least one of ascorbic acid and one or more degradant products of ascorbic acid in such compositions. | 07-07-2011 |
20110160437 | METHODS OF PURIFYING ANTI A BETA ANTIBODIES - The present application provides methods of purifying Aβ binding proteins having a Fc region, for example, anti-Aβ antibodies or antibody fusions, by adsorbing the Aβ binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed Aβ binding protein. The present application also features methods of eluting the purified Aβ binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided. | 06-30-2011 |
20110159011 | USES OF IL-22, IL-17, AND IL-1 FAMILY CYTOKINES IN AUTOIMMUNE DISEASES - Methods of detecting inflammatory disorders using IL- 1 isoforms are provided. Methods of treating an inflammatory disorder with an anti-IL-1 antibody are also provided. Methods of treating an inflammatory disorder with an anti-IL-1 antibody and at least one of an anti-IL-22 antibody, an anti-IL-17 antibody, or an anti-TNFα antibody are also provided. | 06-30-2011 |
20110150893 | ANTI-TRKB MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes. | 06-23-2011 |
20110144176 | MACROLIDES AND METHODS FOR PRODUCING SAME - This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them. | 06-16-2011 |
20110136851 | Sucralose Formulations To Mask Unpleasant Tastes - The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH from about 2 to about 5. The invention is further directed to medicinal compositions comprising such a liquid excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liquid excipient bases. | 06-09-2011 |
20110136772 | SUGAR COATINGS AND METHODS THEREFOR - Compositions particularly useful as coatings for solid dosage forms of therapeutic agents are provided, as are solid dosage forms comprising such coatings, processes for preparing such solid dosage forms, and the products of those processes. The coating compositions generally provide excellent strength and resistance to cracking, even when applied to flexible/swellable tablet cores such as hydrogel-type cores. The compositions also exhibit excellent odor-blocking characteristics. | 06-09-2011 |
20110123560 | Infectious Bursal Disease Virus Antigenic Isolates And Vaccines - Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate. | 05-26-2011 |
20110111018 | COATED TABLET FORMULATIONS AND USES THEREOF - The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets. | 05-12-2011 |
20110110980 | HETERLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN - The invention provides methods of inducing an antigen-specific immune response in a subject by using a combination of immunogenic compositions. Generally, the method involves administering to the subject an effective amount of two different immunogenic compositions, both of which comprise bluetongue virus serotype 8. | 05-12-2011 |
20110108761 | METHODS OF MAKING SELF-STEAMING COMPOSITIONS AND ARTICLES COMPRISING SUCH COMPOSITIONS - A method of making a self-steaming composition is provided, said method comprising mixing a fuel component, a water manager component, and water, wherein the fuel component comprises carbon and wherein the method comprises prewetting the carbon prior to mixing the carbon with the water manager component. | 05-12-2011 |
20110105509 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS - Disclosed are compounds of Formula (I): | 05-05-2011 |
20110091559 | COMPOSITIONS COMPRISING ADJUVANT, MACROLIDE AND PROTEINACEOUS ANTIGEN AND METHODS OF USE THEREOF - The invention is directed to compositions comprising an oil adjuvant, a macrocyclic lactone effective for the prevention or control of parasitic infection in a warm-blooded animal and an immunizing amount of at least one immunogenic polypeptide and methods of use thereof. | 04-21-2011 |
20110091539 | Micronized Tanaproget and Compositions Containing Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 04-21-2011 |
20110091478 | METHODS OF USING ANTIBODIES AGAINST HUMAN IL-22 - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 04-21-2011 |
20110085994 | Sunscreen Compositions - The present invention provides a taste-masked sunscreen composition comprising at least one sunscreen and a spider ester wherein the sunscreen and the spider ester are in intimate association. A method of making the taste-masked sunscreen composition is provided. | 04-14-2011 |
20110060265 | IMPLANTABLE SHUNT OR CATHETER ENABLING GRADUAL DELIVERY OF THERAPEUTIC AGENTS - An implantable catheter or shunt for draining fluid from a body cavity. The catheter or shunt body has a wall structure that carries one or more therapeutic agents in a manner enabling release of the therapeutic agent from the wall structure in situ after surgical implantation of the catheter or shunt body. The therapeutic agent can be gradually released over time to prevent infection, inhibit tissue ingrowths, and/or provide some other desired medicinal purpose. As an example, the therapeutic agent can be rapamycin or an mTOR inhibitor. According to some contemplated embodiments of the present invention, the therapeutic agent carried by the catheter/shunt is rechargeable or refillable in situ so that the therapeutic agent can be gradually released from the catheter/shunt over the expected useful life of the catheter/shunt. | 03-10-2011 |
20110039839 | Cyanopyrroles - This invention provides a progesterone receptor antagonist of formula 1 having the structure | 02-17-2011 |
20110034526 | Benzimidazole Compounds - This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: | 02-10-2011 |
20110034513 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production - Compounds of Formula (I), | 02-10-2011 |
20110033489 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 02-10-2011 |
20110033451 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 02-10-2011 |
20110028455 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors - Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is —O—, —N(R | 02-03-2011 |
20110027329 | Single-use, Disposable Strip For Application Of Topical Compositions - A topical treatment strip comprising a substrate having two surfaces with a topical composition carried thereupon. The treatment strip can be used to treat two surfaces of subject as such as both lips simultaneously. Methods include methods of manufacture and methods of use. | 02-03-2011 |
20110027324 | O-DESMETHYL-VENLAFAXINE FOR TREATING MAJOR DEPRESSIVE DISORDER - The present invention provides methods for treating MDD. In general, the methods comprise administering to a patient in need thereof a daily dose of about 50 mg ODV or an equivalent amount of a pharmaceutically acceptable salt thereof. In certain embodiments, a patient in need of treatment is characterized by a primary diagnosis of MDD. In some embodiments, the dose is administered as a single daily dose. In one set of embodiments, the methods involve administering an oral dosage form comprising the succinate salt of ODV. | 02-03-2011 |
20110027292 | Protein Formulations with Reduced Viscosity and Uses Thereof - Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation. | 02-03-2011 |
20110020372 | FOLLISTATIN DOMAIN CONTAINING PROTEINS - The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration. | 01-27-2011 |
20110020348 | PHARMACEUTICAL COMPOSITIONS AND METHODS USING SECRETED FRIZZLED RELATED PROTEIN - Pharmaceutical compositions and methods of use in regulation of mammalian bone forming activities of sFRPs (secreted frizzled-related proteins) are disclosed. sFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes like tissue polarity, embryonic development, and tumorigenesis. A sFRP was isolated from human osteoblast cells and identified as sFRP-1 (also known as SARP-2) and shown to be regulated by osteogenic agents in hOB cells in a differentiation selective manner, modulating the life of osteoblasts/preosteocytes. An sFRP-1 knock-out mouse was generated and deletion of sFRP-1 was found to not affect nonskeletal tissues, skeletal morphology or cortical bone development, while resulting in increased trabecular bone formation, decreased osteoblast and osteocyte apoptosis and increased osteoprogenitor differentiation. | 01-27-2011 |
20110014624 | Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins - The present invention provides methods of identifying a clonal population of cells suitable for large-scale production of a protein of interest. The invention further provides methods for high-throughput screening for genetic rearrangements in the gene encoding the protein of interest, whereby the absence of a deletion in the gene encoding the protein of interest indicates that the cell is suitable for large-scale production of the protein of interest. | 01-20-2011 |
20100331333 | Imidazo [1,2-B] Pyridazine Compounds - This invention relates generally to imidazo[1,2-b]pyridazine-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: | 12-30-2010 |
20100324073 | Pyrazolo [1,5-A] Pyrimidine Compounds - This invention relates generally to pyrazolo[1,5- | 12-23-2010 |
20100324066 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERA- ZINYL)PROPOXY]-3-QUINOLINECARBONITRILE AND METHODS OF PREPARING THE SAME - This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2θ angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about 115° C. | 12-23-2010 |
20100323005 | Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen - Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets. | 12-23-2010 |
20100322942 | THERAPEUTIC AND PROPHYLACTIC METHODS FOR NEUROMUSCULAR DISORDERS - The disclosure provides methods for treating neuromuscular disorders in mammals. The disclosed methods include administering therapeutically effective amounts of a GDF-8 inhibitor and a corticosteroid to a subject susceptible to, or having, a neuromuscular disorder, so as to maintain desirable levels of muscle function. | 12-23-2010 |
20100311839 | Burst Drug Release Compositions - A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation. | 12-09-2010 |
20100293118 | METHODS AND SYSTEMS FOR PREDICTING PROTEIN-LIGAND COUPLING SPECIFICITIES - The invention provides methods and systems for predicting or evaluating protein-ligand coupling specificities. A pattern recognition model can be trained by selected sequence segments of training proteins which have a specified ligand coupling specificity. Each selected sequence segment is believed to include amino acid residue(s) that may contribute to the ligand coupling specificity of the corresponding training protein. Sequence segments in a protein of interest can be similarly selected and used to query the trained model to determine if the protein of interest has the same ligand coupling specificity as the training proteins. In one embodiment, the pattern recognition model employed is a hidden Markov model which is trained by concatenated cytosolic domains of GPCRs which have interaction preference to a specified class of G proteins. This trained model can be used to evaluate G protein coupling specificity of orphan GPCRs. | 11-18-2010 |
20100292198 | CYCLIC PROGESTIN REGIMENS AND KITS - A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen. | 11-18-2010 |
20100291240 | Method to Stabilize a Dietary Supplement to Facilitate Joint Health in Humans - The present invention provides for compositions comprising glucosamine wherein the glucosamine has improved and/or enhanced stability. Additionally, the present invention provides for methods of stabilizing compositions for use in preparing an oral dosage form comprising glucosamine. | 11-18-2010 |
20100286071 | Finger-1 Peptide Analogs of the TGF-Beta Superfamily - Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics. | 11-11-2010 |
20100273772 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) - Disclosed are compounds of Formula I: | 10-28-2010 |
20100267715 | Polymorph Form II of Tanaproget - Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject. | 10-21-2010 |
20100266505 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 10-21-2010 |
20100249207 | SYNTHESIS OF PYRROLIDINE COMPOUNDS - Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms. | 09-30-2010 |
20100249169 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF - The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids. | 09-30-2010 |
20100234422 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor - Compounds of the following structure are provided, wherein n, R | 09-16-2010 |
20100221445 | O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF - A combination product containing at least two active compounds, O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and bazedoxifene or a pharmaceutically acceptable salt thereof is described. Also described are methods of making and using this combination product to treat a variety of conditions associated with low circulating estrogen levels or low estrogen receptor activity. | 09-02-2010 |
20100221187 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment. | 09-02-2010 |
20100204245 | Amino-pyridines As Inhibitors Of Beta-secretase - The present invention provides an amino-pyridine compound of formula I | 08-12-2010 |
20100204228 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor - In one embodiment, compounds of the following structure are described, wherein R | 08-12-2010 |
20100197645 | Thioamide Derivatives as Progesterone Receptor Modulators - Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies. | 08-05-2010 |
20100189789 | Micronized Tanaproget, Compositions, and Methods of Preparing the Same - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 07-29-2010 |
20100184786 | Polar Quinazolines - Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): | 07-22-2010 |
20100168194 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase - The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles. | 07-01-2010 |
20100168106 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation - The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I | 07-01-2010 |
20100168091 | Imidazole Amines As Inhibitors Of Beta-secretase - The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated 3-amyloid deposits or 3-amyloid levels in a patient. | 07-01-2010 |
20100166752 | Anti A Beta Antibody Formulation - The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration. | 07-01-2010 |
20100160622 | METHOD FOR CONTROLLING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE MOLECULAR WEIGHT USING CARBON DIOXIDE - The present invention provides improved methods for producing a solution containing high molecular weight isolated | 06-24-2010 |
20100158953 | METHOD FOR CONTROLLING STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A POLYSACCHARIDE MOLECULAR WEIGHT - The present invention provides improved methods for producing a solution containing high molecular weight isolated | 06-24-2010 |
20100158924 | Expression of the cysteine protease legumain in vascular and inflammatory diseases - The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and/or ZB-1 activity, expression, and/or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and/or preventing vascular disorders/diseases and inflammatory disorders/diseases. | 06-24-2010 |
20100151060 | BOTANICAL BUTTER STICK LIP BALM - A stick lip balm with efficacious amounts of natural moisturizer and organoleptic/sensory attributes of lip feel associated with moisturizers and emollients is provided. The lip balm of the invention comprises at least 90% botanically derived materials and can be formed into a stick sufficiently robust to substantially retain the stick shape under normal conditions of shipping, storage and usage. A method of making the stick lip balm is also provided. | 06-17-2010 |
20100137363 | Substituted Indoles And Methods Of Their Use - The present invention relates generally to substituted indoles and methods of using them. | 06-03-2010 |
20100132059 | TEMPERATURE-INDUCED POLYNUCLEOTIDES AND USES THEREFOR - The present invention is based on the discovery that the transcriptional activity of both hamster mammary tumor 7 (HMT-7) and hamster layilin genes are increased when Chinese Hamster Ovary (CHO) cells are cultured at temperatures lower than 37° C. The present invention provides novel genomic, cDNA, and protein sequences of HMT-7 and a novel genomic sequence for hamster layilin. Included in the genomic sequences are novel temperature-induced promoter sequences for each; two promoter sequences are provided for HMT-7 and one promoter sequence is provided for layilin. The invention additionally provides antisense and siRNA molecules to the nucleic acid molecules of HMT-7. The invention also provides genetically engineered expression vectors comprising the novel temperature-induced promoters of the invention, which are particularly useful as part of a mammalian temperature-inducible expression system. The invention also provides host cells and/or transgenic animals comprising the novel nucleic acid molecules of the invention. The invention further provides methods of using the polynucleotides of the invention, e.g., for temperature-induced transgene expression. | 05-27-2010 |
20100129360 | ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 AND USES THEREFOR - This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders. | 05-27-2010 |
20100120782 | ENDOPARASITICIDAL GEL COMPOSITION - A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal. | 05-13-2010 |
20100120725 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production - Compounds of Formula I, | 05-13-2010 |